Skip to main content

Publication: Three statistical publications

Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials (ONLINE).
Asleh K, Tu D, Gao D, Bramwell V, Levine MN, Pritchard KI, Shepherd LE, Nielsen TO. Clin Cancer Res 2021.
 
Purpose: Accurate immunohistochemical biomarkers incorporating nestin positivity or inositol polyphosphate-4-phosphate (INPP4B) loss have recently been optimized to identify the basal-like intrinsic breast cancer subtype regardless of estrogen, progesterone or Her2 status. We examined the predictive capacity of these basal biomarkers in the CCTG MA.5 chemotherapy and MA.12 endocrine therapy trials.
 
Publication on statistical methodology and quality of life: A Joint Model for Longitudinal Outcomes with Potential Floor or Ceiling Effects and Survival Times, with Applications to Analysis of Quality of Life Data from a Cancer Clinical Trial (ONLINE).
Wang Z, Xu H, Liu H, Song H, Tu D. Stat 2021.
 
Longitudinal data on patient reported outcomes (PROs), such as quality of life of patients, are frequently collected in clinical trials and other medical studies. Joint analysis of these data with survival times may improve the accuracy of statistical inferences, especially when PRO measurements may be missing after the death of patients. Classical linear mixed models are often used as the models for the longitudinal measurements in a joint analysis but it may not be suitable for longitudinal PRO measurements with potential floor or ceiling effect caused by a large portion of patients who report either a maximum or minimum score. In this paper, we introduce a new joint model which uses a longitudinal Tobit model for the longitudinal outcomes with potential floor and ceiling effect and a Cox proportional hazard model for survival time with a random effect connecting these two models. An estimation procedure based on the partial likelihood and Laplace approximation is developed to estimate the parameters in both models and a random weighting method is proposed to calculate the variances of these parameter estimators. Performances of the proposed procedures are evaluated through simulation studies and an application to the analysis of quality of life data from a clinical trial.
 
 
Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens (ONLINE).
Quintanilha JCF, Wang J, Sibley AB, Xu W, Espin-Garcia O, Jiang C, Etheridge AS, Ratain MJ, Lenz HJ, Bertagnolli M, Kindler HL, Dickler MN, Venook A, Liu G, Owzar K, Lin D, Innocenti F. Int J Cancer n/a: 2021.